Navigation Links
HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College
Date:9/8/2011

SAN DIEGO, Calif., Sept. 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Zhejiang Chinese Medical University Life Science College. The collaboration agreement will accelerate the global drug development of China's novel Traditional Chinese Medicines (TCM).

The partnership is expected to bring productive synergy between the two parties. Zhejiang Chinese Medical University Life Science College, a prominent traditional Chinese medicine university in southern China, is recognized for its strength in leading-edge research in TCM.  HUYA has a strong commitment toward developing novel therapeutics from TCM in areas of unmet medical needs.  HBI-3000, HUYA's novel anti-arrhythmic compound currently in development in both China and the U.S., was originally derived from a TCM.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.

"The alliance with Zhejiang Chinese Medical University Life Science College will further strengthen HUYA's collaborative efforts with the faculty and researchers of the university," said Clement Gingras, HUYA's CTO and COO, China. "Together, HUYA and Zhejiang Chinese Medical University Life Science College will help advance the progression of TCM to the global markets, benefiting patients worldwide."

Dr. Zhishan Ding, Associate Dean of Zhejiang Chinese Medical University Life Science College, commented, "Our College is dedicated to promoting TCM innovations. We are delighted to collaborate with HUYA and together we will share the commitment towards the global development of novel therapeutics from TCM in areas of unmet medical need."

ABOUT HUYA BIOSCIENCE INTERNATIONAL

HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com

ABOUT ZHEJIANG TCM UNIVERSITY LIFE SCIENCE COLLEGE

Zhejiang Chinese Medical University Life Science College, established in April 2000, is a successor of the Institute of Molecular Medicine. The college has six research departments: Biochemistry, Genetics and Molecular Biology, Cell Biology, Microbiology and Immunology, General Biology, and Clinical Laboratory Science. With well-defined missions, elite faculty, and outstanding educational subjects, Zhejiang Chinese Medical University Life Science College is now a leading institute for TCM in China. It has received various awards, developed two new drugs (one successfully marketed), undertaken a significant number of projects, and published numerous papers. For more information, please visit http://sk.zjtcm.net/

CONTACT

USA:
Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International
+1.858.798.8800
ywang@huyabio.com

China:
Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International
+86.21.51323312
vxia@huyabio.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
2. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
3. BD Biosciences Announces Winners of Research Grant Program
4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
5. Numira Biosciences Names New Board Member
6. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
11. Roka Bioscience Participates in the International Association for Food Protection Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 Regen BioPharma Inc. (OTCQB: ... of Molecular Sciences a team of scientists in ... have demonstrated that expression of NR2F6 in patients with early ... NR2F6 in patient,s cervical cancer tissue as well as in ... "This is an interesting study and the first that I ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kara Dwyer Dodge grew up hearing stories ... a third-generation fisherman in Scituate, Mass., found a sea turtle entangled in the lines of ... the turtle became a minor sensation because no one could remember ever seeing one so ...
(Date:12/6/2016)... ... December 06, 2016 , ... Discovering new clues to natural treatments ... lasers what’s happening in our brains. And searching for keys to our immune systems ... being honored with the 2017 Edith and Peter O’Donnell Awards by ...
(Date:12/6/2016)... and SAN DIEGO , Dec. 6, ... appointment of Santosh Kesari , MD, PhD, FANA, ... leverage his experience in neurology and clinical trials to ... cell for treatment of stroke. The AmnioStem product is a ... has previously shown therapeutic activity in animal models of ...
Breaking Biology Technology:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
(Date:11/17/2016)... Calif. , Nov. 17, 2016  AIC announces that it has just released ... in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a high ...
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
Breaking Biology News(10 mins):